At the tipping point for epigenetic therapies in cancer

Journal of Clinical Investigation

Volumn 124, Issue 1, 2014, Pages 14-16

  Jones, Peter A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR T BET;

CANCER CELL CULTURE; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; DNA METHYLATION; ENZYME ACTIVITY; EPIGENETICS; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HIGH THROUGHPUT SEQUENCING; HISTONE MODIFICATION; HUMAN; IMMUNOSURVEILLANCE; LARGE CELL LYMPHOMA; MYELODYSPLASTIC SYNDROME; OVARY CYCLE; PRIORITY JOURNAL; REVIEW; SILENCER GENE; SOLID TUMOR; TUMOR GROWTH;

EID: 84892904531     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74145     Document Type: Review

References (16)

1. Google Scholar. http://scholar.google.com. Accessed October 28, 2013
2. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013;153(1):38-55
3. Weisenberger DJ. Characterizing DNA methylation alterations from The Cancer Genome Atlas. J Clin Invest. 2014;124(1):17-23
4. ENCODE Project Consortium, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74
5. Issa J-P. Aging and epigenetic drift: a vicious circle. J Clin Invest. 2014;124(1):24-29
6. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124(1):30-39
7. Cihak A, Sorm F. Biochemical effects and metabolic transformation of 5-azacytidine in Escherichia coli. Collect Czech Chem Commun. 1965;30(6):2091-2102
8. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980; 20(1):85-93
9. Fenaux P, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232
10. Navada SC, Steinmann J, Lübbert M, Silverman LR. Clinical development of demethylating agents in hematology. J Clin Invest. 2014; 124(1):40-46
11. Garcia-Manero G, et al. Randomized open-label phase II study of decitabine in patients with lowor intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013;31(20):2548-2553
12. Lübbert M, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987-1996
13. Kantarjian HM, et al. Results From the Dose Escalation Phase of a Randomized Phase 1-2 First-in- Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. Presented at: The 54th American Society of Hematology Annual Meeting and Exposition. December 8-11, 2012. Atlanta, Georgia, USA. https://ash.confex. com/ash/2012/webprogram/Paper49626. html. Accessed November 5, 2013
14. Treppendahl MB, Kristensen LS, Grønbæk K. Predicting response to epigenetic therapy. J Clin Invest. 2014;124(1):47-55
15. Ahuja N, Easwaran H, Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest. 2014;124(1):56-63
16. Campbell RM, Tummino PJ. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest. 2014; 124(1):64-69.